Cirrhosis

Cirrhosis is the end-stage, irreversible diffuse hepatic fibrosis characterized by the replacement of normal liver architecture with regenerative nodules and fibrous septa, leading to profound impairment of hepatic function and portal blood flow. It represents the final common pathway of chronic liver injury from various etiologies, resulting in progressive loss of hepatocytes, disruption of the hepatic microcirculation, and the development of portal hypertension and its sequelae, including ascites, hepatic encephalopathy, and portosystemic shunting. In veterinary medicine, cirrhosis is most commonly recognized in dogs and less frequently in cats, and it is a major cause of chronic liver disease and mortality.

The etiologies of cirrhosis in dogs and cats are diverse and often multifactorial. Chronic hepatitis, which can be of infectious, toxic, metabolic, or immune-mediated origin, is the most common precursor. Specific causes include: infectious agents such as canine adenovirus-1 (infectious canine hepatitis), leptospirosis (Leptospira interrogans serovars), and in cats, feline infectious peritonitis (FIP) caused by a mutated feline coronavirus; chronic cholangitis/cholangiohepatitis in cats, often associated with bacterial infections (E. coli, Enterococcus spp.) and concurrent inflammatory bowel disease or pancreatitis (triaditis); toxic insults from drugs and chemicals, including long-term administration of phenobarbital, primidone, phenytoin, and other antiepileptics, as well as exposure to aflatoxins, pyrrolizidine alkaloids (from Senecio, Crotalaria, and Heliotropium plants), heavy metals, and certain chemotherapeutic agents; metabolic disorders such as copper-associated hepatitis in Bedlington Terriers, West Highland White Terriers, Skye Terriers, and Doberman Pinschers, and less commonly iron overload; autoimmune and immune-mediated hepatitis, where an aberrant immune response targets hepatocytes; and genetic predispositions in certain breeds, including the Labrador Retriever, Cocker Spaniel, and German Shepherd. In many cases, the inciting cause remains idiopathic (chronic idiopathic hepatitis). Chronic biliary tract disease, such as extrahepatic bile duct obstruction or chronic cholecystitis, can also progress to secondary biliary cirrhosis. Additionally, chronic passive congestion due to right-sided congestive heart failure or chronic hepatic vein obstruction (Budd-Chiari syndrome) can lead to cardiac cirrhosis.

Cirrhosis is a significant cause of morbidity and mortality in dogs, with a reported prevalence of approximately 0.5-1% in the general canine population, but it is less common in cats. It typically affects middle-aged to older animals, with a mean age of onset around 7-10 years in dogs and 10-12 years in cats. There is no strong sex predilection, although some studies suggest a slight male predominance in dogs. Breed predispositions are notable: Doberman Pinschers, Cocker Spaniels, Labrador Retrievers, German Shepherds, and Bedlington Terriers are at higher risk for chronic hepatitis and cirrhosis. In cats, chronic cholangitis is more common in middle-aged to older cats, and certain breeds like the Persian and Siamese may be predisposed. Geographic variations exist, with copper-associated hepatitis more prevalent in regions where Bedlington Terriers are common, and leptospirosis is more frequent in areas with high rainfall and wildlife reservoirs. Environmental factors such as exposure to hepatotoxic plants or contaminated feed can lead to outbreaks of aflatoxicosis-induced cirrhosis in certain regions.

The pathophysiology of cirrhosis involves a complex cascade of hepatocyte injury, inflammation, and fibrosis. Chronic injury leads to hepatocyte apoptosis and necrosis, triggering an inflammatory response with activation of Kupffer cells and recruitment of neutrophils and lymphocytes. These inflammatory cells release cytokines, including transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF), and tumor necrosis factor-alpha (TNF-α), which activate hepatic stellate cells (Ito cells) in the space of Disse. Activated stellate cells transform into myofibroblast-like cells that produce excessive extracellular matrix (ECM) proteins, particularly collagen type I and III, leading to fibrosis. As fibrosis progresses, it forms fibrous septa that interconnect portal tracts and central veins, disrupting the normal lobular architecture. The liver attempts to regenerate, forming regenerative nodules, but these nodules are not functionally normal and further distort the architecture. The fibrous septa and nodules impede blood flow through the hepatic sinusoids, increasing intrahepatic vascular resistance and leading to portal hypertension. Portal hypertension causes the development of portosystemic shunts (acquired), splanchnic vasodilation, and decreased effective arterial blood volume, activating the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system, leading to sodium and water retention and ascites. Impaired hepatic synthetic function results in hypoalbuminemia, decreased clotting factor synthesis (II, VII, IX, X), and reduced urea synthesis. Decreased hepatic clearance of ammonia and other neurotoxins (e.g., mercaptans, false neurotransmitters) leads to hepatic encephalopathy. Additionally, impaired bile flow and reduced bile acid synthesis cause cholestasis and malabsorption of fats and fat-soluble vitamins. The loss of hepatic metabolic capacity also affects drug metabolism, glucose homeostasis, and hormone regulation.

Predisposing factors for cirrhosis include: breed-specific genetic mutations, such as the COMMD1 gene mutation in Bedlington Terriers causing copper accumulation; chronic administration of hepatotoxic drugs, especially antiepileptics like phenobarbital and primidone; dietary factors, including high copper content in certain commercial diets or exposure to aflatoxin-contaminated feed; concurrent diseases that promote chronic inflammation, such as inflammatory bowel disease, pancreatitis, and cholangitis in cats; infectious agents, particularly leptospirosis and chronic viral infections; metabolic disorders like diabetes mellitus and hyperadrenocorticism, which can contribute to hepatic lipidosis and inflammation; and age-related decline in hepatic regenerative capacity. Environmental factors, such as exposure to toxic plants (e.g., Senecio, Crotalaria) or industrial chemicals, also increase risk. Immunosuppression, whether due to concurrent illness or immunosuppressive therapy, may predispose to chronic infections that affect the liver. Additionally, obesity and hepatic lipidosis can exacerbate liver injury and fibrosis.

Clinical signs of cirrhosis are often insidious and may not become apparent until significant hepatic dysfunction has occurred. Early signs are nonspecific and include lethargy, depression, anorexia, weight loss, and intermittent vomiting and diarrhea. As the disease progresses, more specific signs of hepatic failure and portal hypertension emerge. These include: polyuria and polydipsia (due to impaired urea synthesis and altered ADH metabolism), jaundice (icterus) of the mucous membranes and skin, ascites (abdominal distension due to fluid accumulation), and hepatic encephalopathy, which manifests as behavioral changes, disorientation, circling, head pressing, ataxia, seizures, and coma. Gastrointestinal signs such as hematemesis or melena may occur due to gastric ulceration or bleeding from esophageal varices (rare in dogs and cats). Physical examination may reveal hepatomegaly or microhepatia (small, shrunken liver), abdominal distension with a fluid wave, muscle wasting, poor body condition, and a dull, unkempt haircoat. In advanced stages, peripheral edema, petechiae or ecchymoses (due to coagulopathy), and fever (if secondary infection) may be present. In cats, chronic cholangitis-associated cirrhosis may present with intermittent jaundice, vomiting, and weight loss.

Differential diagnoses for cirrhosis include: (1) Chronic hepatitis without cirrhosis – distinguished by histopathology showing inflammation and fibrosis but without complete architectural distortion and regenerative nodules; (2) Hepatic neoplasia (e.g., hepatocellular carcinoma, lymphoma, metastatic disease) – may present with hepatomegaly, weight loss, and elevated liver enzymes; imaging and biopsy are needed; (3) Extrahepatic bile duct obstruction (e.g., due to pancreatitis, cholelithiasis, neoplasia) – characterized by marked hyperbilirubinemia, elevated ALP and GGT, and ultrasonographic evidence of biliary distension; (4) Portosystemic shunt (congenital or acquired) – may cause similar signs of hepatic encephalopathy and elevated bile acids, but imaging (Doppler ultrasound, CT angiography) and histopathology differentiate; (5) Hepatic lipidosis (especially in cats) – severe jaundice and hepatomegaly, but histopathology shows marked vacuolation of hepatocytes without fibrosis; (6) Leptospirosis – acute onset of fever, icterus, and renal signs, with positive serology or PCR; (7) Feline infectious peritonitis (FIP) – in cats, with pyogranulomatous inflammation and positive coronavirus serology/immunohistochemistry; (8) Copper-associated hepatopathy – may be a precursor to cirrhosis; liver copper quantification is diagnostic; (9) Chronic cholangitis/cholangiohepatitis in cats – may progress to cirrhosis but is distinguished by biliary tract inflammation and culture; (10) Right-sided congestive heart failure – causes hepatic congestion and ascites, but cardiac evaluation (echocardiography) reveals underlying heart disease.

The diagnostic approach to cirrhosis should be systematic: (1) Obtain a thorough history and physical examination, with attention to breed, age, drug exposure, and clinical signs. (2) Perform baseline laboratory tests: complete blood count (CBC), serum biochemistry profile, urinalysis, and fasting serum bile acids. (3) If liver disease is suspected, perform abdominal ultrasonography to assess liver size, echogenicity, nodularity, and the presence of ascites or portosystemic shunts. (4) If ascites is present, perform abdominocentesis and analyze the fluid (typically a modified transudate with low protein and low cell count in cirrhosis). (5) Consider additional tests: coagulation profile (prothrombin time, activated partial thromboplastin time, fibrinogen, D-dimers), ammonia tolerance test, and serology/PCR for infectious agents (e.g., Leptospira, feline coronavirus). (6) If imaging and lab tests are inconclusive or to confirm the diagnosis, obtain liver biopsy via ultrasound-guided needle biopsy, laparoscopic biopsy, or surgical wedge biopsy. Histopathology is the gold standard for diagnosing cirrhosis, revealing diffuse fibrosis, regenerative nodules, and architectural distortion. (7) In cases of suspected copper-associated hepatitis, measure hepatic copper concentration (normal < 400 ppm dry weight; > 2000 ppm indicates significant accumulation). (8) In cats with suspected cholangitis, perform bile culture and cytology. (9) If hepatic encephalopathy is suspected, measure blood ammonia (fasting or post-prandial) and consider brain imaging to rule out other causes. (10) In cases of suspected portosystemic shunting, perform Doppler ultrasonography or CT angiography.

Hematology: CBC may reveal mild to moderate non-regenerative anemia (due to chronic disease, gastrointestinal bleeding, or decreased erythropoietin), microcytosis (in dogs with portosystemic shunting), and target cells or acanthocytes. Leukocytosis may be present if there is concurrent infection or inflammation. Thrombocytopenia can occur due to decreased thrombopoietin production, portal hypertension-associated splenic sequestration, or disseminated intravascular coagulation (DIC). Serum Biochemistry: Liver enzyme elevations are variable; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) may be mildly to moderately elevated, but in end-stage cirrhosis, they may be normal due to loss of hepatocyte mass. Alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) are often elevated due to cholestasis. Hypoalbuminemia is common due to decreased synthesis. Blood urea nitrogen (BUN) may be low due to decreased urea synthesis. Hyperbilirubinemia may be present, especially in advanced disease. Glucose may be low due to impaired gluconeogenesis. Cholesterol may be low. Electrolyte abnormalities include hyponatremia (due to dilution from water retention) and hypokalemia (due to poor intake, vomiting, or diuretic use). Coagulation abnormalities: Prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT) due to decreased synthesis of clotting factors. Urinalysis: Urine specific gravity may be low (isosthenuria) due to impaired concentrating ability; bilirubinuria may be present, especially in dogs. Blood Gas Analysis: May reveal metabolic alkalosis due to vomiting or diuretic use, or metabolic acidosis in advanced liver failure. Specific Biomarkers: Serum bile acids (fasting and 2-hour post-prandial) are typically elevated, especially in cases with portosystemic shunting. Blood ammonia may be elevated, particularly after a meal. In cats, feline pancreatic lipase immunoreactivity (fPLI) may be elevated if concurrent pancreatitis. C-reactive protein (CRP) may be elevated as an inflammatory marker. Serology/PCR: Positive results for Leptospira (MAT or PCR) or feline coronavirus (FIP) may support infectious etiologies.

Radiography: Abdominal radiographs may show microhepatia (small liver) in advanced cirrhosis, or hepatomegaly in early stages. Ascites may cause a ground-glass appearance and loss of abdominal detail. Thoracic radiographs may reveal pleural effusion or signs of right-sided heart failure. Ultrasonography: Abdominal ultrasound is the most valuable imaging modality. Findings include: decreased liver size (microhepatia) with irregular margins, increased echogenicity (diffuse or nodular), coarse echotexture, and the presence of regenerative nodules (which may appear as hypoechoic or hyperechoic foci). The hepatic vasculature may be poorly visualized due to fibrosis. Doppler ultrasound can detect acquired portosystemic shunts, which appear as tortuous vessels connecting the portal vein to the systemic circulation. Ascites is readily identified as anechoic fluid in the peritoneal cavity. Biliary tract abnormalities, such as gallbladder wall thickening or sludge, may be seen. Computed Tomography (CT): CT provides detailed cross-sectional imaging and can better characterize hepatic nodularity, vascular anatomy, and the presence of shunts. CT angiography is particularly useful for detecting portosystemic shunts. Magnetic Resonance Imaging (MRI): MRI is less commonly used but can provide excellent soft tissue contrast and may help differentiate cirrhosis from other hepatic diseases. Endoscopy: Upper gastrointestinal endoscopy may reveal esophageal varices (rare) or gastric erosions/ulcers due to portal hypertension. Fluoroscopy: Not routinely used, but may be helpful for evaluating portosystemic shunts during angiography. Echocardiography: In cases of suspected cardiac cirrhosis, echocardiography is essential to evaluate right heart function and rule out congestive heart failure.

Cytology: Fine-needle aspiration (FNA) of the liver is often performed but has limited diagnostic value for cirrhosis because it only samples a small area and may not capture the architectural changes. FNA may show hepatocytes with variable degeneration, inflammation, and fibrosis, but it cannot reliably distinguish cirrhosis from chronic hepatitis or other diseases. Fluid analysis of ascites: In cirrhosis, ascitic fluid is typically a modified transudate with low protein (< 2.5 g/dL) and low cell count (< 1000 nucleated cells/µL), consistent with portal hypertension. If there is secondary infection (spontaneous bacterial peritonitis), the fluid may have increased neutrophils and bacteria. Histopathology: Liver biopsy is the gold standard for diagnosing cirrhosis. Histological features include: diffuse fibrosis with fibrous septa that bridge portal tracts and central veins, regenerative nodules of hepatocytes, and disruption of the normal lobular architecture. The fibrosis may be micronodular (small nodules) or macronodular (large nodules). There is often infiltration of inflammatory cells (lymphocytes, plasma cells, neutrophils) in the portal tracts and parenchyma. Hepatocyte necrosis and apoptosis may be present. Special stains, such as Masson's trichrome for collagen and reticulin stains, can highlight the fibrosis. In copper-associated hepatitis, rhodanine stain or copper quantification (atomic absorption spectroscopy) is performed. In cats with cholangitis, there may be neutrophilic or lymphocytic inflammation of the bile ducts and portal tracts.

Treatment of cirrhosis is primarily supportive and symptomatic, as the underlying fibrosis is generally irreversible. The goals are to manage complications, slow disease progression, and improve quality of life. (1) Dietary management: Feed a high-quality, highly digestible diet with moderate protein restriction (to reduce ammonia production) but adequate to maintain muscle mass. In dogs, a diet with reduced copper may be beneficial if copper-associated hepatitis is present. Supplement with water-soluble vitamins (B-complex) and fat-soluble vitamins (A, D, E, K) if cholestasis is present. (2) Management of ascites: Restrict sodium intake, and use diuretics such as spironolactone (starting at 1-2 mg/kg PO q12h, can be increased to 4 mg/kg/day) alone or in combination with furosemide (0.5-1 mg/kg PO q12h). Therapeutic abdominocentesis may be performed for severe respiratory distress, but rapid removal of large volumes can lead to hypotension and electrolyte imbalances. (3) Management of hepatic encephalopathy: Reduce protein intake, administer lactulose (0.5-1 mL/kg PO q8h, titrated to produce 2-3 soft stools per day), and use antibiotics such as neomycin (20 mg/kg PO q8h) or metronidazole (7.5-10 mg/kg PO q12h) to reduce ammonia-producing bacteria in the colon. (4) Gastrointestinal ulcer prophylaxis: Use proton pump inhibitors (e.g., omeprazole 0.5-1 mg/kg PO q12h) or H2-receptor antagonists (e.g., famotidine 0.5-1 mg/kg PO q12h) to prevent gastric ulceration. (5) Coagulopathy: If bleeding occurs or before biopsy, administer vitamin K1 (0.5-1.5 mg/kg SC or IM q12h for 2-3 doses) and consider fresh frozen plasma if severe. (6) Hepatoprotectants: S-adenosylmethionine (SAMe) (18-20 mg/kg PO q24h) and silymarin (milk thistle extract) (20-50 mg/kg PO q24h) may have antioxidant and anti-inflammatory effects. Ursodeoxycholic acid (UDCA) (10-15 mg/kg PO q24h) can improve bile flow and reduce hepatocyte injury. (7) Treatment of underlying cause: If copper-associated hepatitis, use copper chelators such as D-penicillamine (10-15 mg/kg PO q12h) or trientine (10-15 mg/kg PO q12h). If infectious (e.g., leptospirosis), use appropriate antibiotics (e.g., doxycycline 5-10 mg/kg PO q12h for 14 days). If immune-mediated, consider immunosuppressive doses of prednisone (1-2 mg/kg PO q12h) or other immunosuppressants, but use with caution due to risk of infection. (8) Management of portal hypertension: In severe cases, surgical placement of a transjugular intrahepatic portosystemic shunt (TIPS) is not commonly performed in veterinary medicine. (9) Supportive care: Provide antiemetics (e.g., maropitant 1 mg/kg SC q24h) for vomiting, appetite stimulants (e.g., mirtazapine 3.75 mg/cat PO q48h in cats, 0.5-1 mg/kg PO q24h in dogs), and fluid therapy with balanced electrolyte solutions, avoiding lactate if severe hepatic dysfunction. (10) Avoid hepatotoxic drugs and adjust dosages of drugs metabolized by the liver.

The prognosis for cirrhosis is generally poor to guarded, as the disease is progressive and irreversible. Median survival time in dogs with cirrhosis is reported to be approximately 1-2 years, but varies widely depending on the underlying cause, severity of clinical signs, and response to treatment. Negative prognostic indicators include: presence of ascites, hepatic encephalopathy, coagulopathy, severe hypoalbuminemia (< 2.0 g/dL), hyperbilirubinemia, and elevated serum creatinine. Dogs with copper-associated hepatitis that are treated early may have a better prognosis. Cats with cirrhosis associated with chronic cholangitis may have a more variable prognosis, with some responding to immunosuppressive therapy. The goal of treatment is to improve quality of life and manage complications; however, most animals eventually succumb to liver failure, complications of portal hypertension, or concurrent disease.

Follow-up care for cirrhosis requires regular monitoring and adjustment of therapy. Initially, re-evaluate the patient every 2-4 weeks until clinical signs are stable, then every 1-3 months thereafter. At each visit, perform a physical examination, body weight, and assessment of ascites and neurological status. Serial laboratory monitoring should include: CBC, serum biochemistry profile (especially liver enzymes, bilirubin, albumin, BUN, glucose, electrolytes), coagulation profile (PT/aPTT), and serum bile acids or ammonia if hepatic encephalopathy is a concern. Urinalysis should be repeated periodically. Abdominal ultrasonography may be repeated every 3-6 months to assess liver size, nodularity, and ascites. Adjust diuretic dosages based on response and electrolyte status. Monitor for drug toxicity, especially with long-term use of hepatotoxic drugs. Provide dietary counseling and ensure adequate caloric intake. In cases of copper-associated hepatitis, monitor liver copper levels with repeat biopsies if indicated. Educate owners on signs of hepatic encephalopathy, bleeding, and ascites, and advise them to seek immediate veterinary care if these occur.

Pearls: (1) Liver biopsy is essential for definitive diagnosis and to identify the underlying cause; do not rely solely on imaging and blood tests. (2) In dogs with chronic hepatitis, consider copper-associated hepatopathy even in non-predisposed breeds; measure liver copper if histopathology suggests. (3) Ascites in cirrhosis is a modified transudate; if the fluid has high protein or cells, consider other causes such as neoplasia or infection. (4) Hepatic encephalopathy can be precipitated by high-protein meals, gastrointestinal bleeding, infection, or electrolyte imbalances; manage these triggers. (5) Use lactulose and antibiotics early in hepatic encephalopathy to reduce ammonia production. (6) In cats, chronic cholangitis is often associated with inflammatory bowel disease and pancreatitis; evaluate the entire gastrointestinal tract. Pitfalls: (1) Do not use corticosteroids indiscriminately in chronic hepatitis without a confirmed immune-mediated component, as they can worsen fibrosis and increase infection risk. (2) Avoid over-restriction of protein in the diet, as it can lead to malnutrition and worsen hypoalbuminemia. (3) Do not perform abdominocentesis too rapidly or remove large volumes, as it can cause hypotension and electrolyte shifts. (4) Do not use NSAIDs or other hepatotoxic drugs in patients with cirrhosis. (5) Be cautious with the use of sedatives and anesthetics in patients with hepatic dysfunction; use drugs that are not heavily metabolized by the liver. (6) Do not forget to check coagulation status before liver biopsy to avoid bleeding complications.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are commonly used in the management of cirrhosis: (1) Diuretics: Spironolactone: Dogs: 1-2 mg/kg PO q12h, can be increased to 4 mg/kg/day; Cats: 1-2 mg/kg PO q12h. Furosemide: Dogs: 1-2 mg/kg PO q12h, may be increased to 4 mg/kg q8h; Cats: 0.5-1 mg/kg PO q12h. (2) Lactulose: Dogs and Cats: 0.5-1 mL/kg PO q8h, titrate to produce 2-3 soft stools per day. (3) Antibiotics for hepatic encephalopathy: Neomycin: Dogs: 20 mg/kg PO q8h; Cats: 20 mg/kg PO q8h. Metronidazole: Dogs: 7.5-10 mg/kg PO q12h; Cats: 7.5-10 mg/kg PO q12h. (4) Gastroprotectants: Omeprazole: Dogs: 0.5-1 mg/kg PO q12h; Cats: 0.5-1 mg/kg PO q12h. Famotidine: Dogs: 0.5-1 mg/kg PO q12h; Cats: 0.5-1 mg/kg PO q12h. (5) Hepatoprotectants: S-adenosylmethionine (SAMe): Dogs: 18-20 mg/kg PO q24h; Cats: 18-20 mg/kg PO q24h. Silymarin: Dogs: 20-50 mg/kg PO q24h; Cats: 20-50 mg/kg PO q24h. Ursodeoxycholic acid (UDCA): Dogs: 10-15 mg/kg PO q24h; Cats: 10-15 mg/kg PO q24h. (6) Copper chelators: D-penicillamine: Dogs: 10-15 mg/kg PO q12h, administer on an empty stomach; Cats: 10-15 mg/kg PO q12h. Trientine: Dogs: 10-15 mg/kg PO q12h; Cats: 10-15 mg/kg PO q12h. (7) Vitamin K1: Dogs and Cats: 0.5-1.5 mg/kg SC or IM q12h for 2-3 doses before procedures or if coagulopathy. (8) Antiemetics: Maropitant: Dogs: 1 mg/kg SC q24h; Cats: 1 mg/kg SC q24h. (9) Appetite stimulants: Mirtazapine: Cats: 3.75 mg/cat PO q48h; Dogs: 0.5-1 mg/kg PO q24h. (10) Corticosteroids (for immune-mediated hepatitis): Prednisone: Dogs: 1-2 mg/kg PO q12h, taper gradually; Cats: 1-2 mg/kg PO q12h, taper gradually. (11) Antibiotics for leptospirosis: Doxycycline: Dogs: 5-10 mg/kg PO q12h for 14 days; Cats: 5-10 mg/kg PO q12h for 14 days. (12) Fluid therapy: Use balanced electrolyte solutions (e.g., Normosol-R, Plasma-Lyte) with potassium supplementation as needed; avoid lactate-containing fluids if severe hepatic dysfunction. Dosages should be adjusted for renal or hepatic impairment, and drug interactions should be considered, especially with drugs that are highly protein-bound or hepatically metabolized.

Evidence-based literature on cirrhosis in veterinary medicine is limited, but several key studies and consensus statements provide guidance. The ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in dogs (2014) emphasizes the importance of liver biopsy for diagnosis and the use of immunosuppressive therapy in immune-mediated cases. Studies have shown that copper-associated hepatitis in Bedlington Terriers is linked to a mutation in the COMMD1 gene, and early treatment with copper chelators can improve outcomes. In cats, chronic cholangitis is often associated with inflammatory bowel disease and pancreatitis, and treatment with immunosuppressive doses of prednisolone and antibiotics (e.g., amoxicillin-clavulanate) has been recommended based on retrospective studies. A study by Webster et al. (2019) reported that dogs with cirrhosis have a median survival time of 1.2 years, with ascites and hyperbilirubinemia being negative prognostic indicators. Another study by Dirksen et al. (2017) found that treatment with SAMe and silymarin improved liver enzyme activities and clinical signs in dogs with chronic hepatitis. The use of ursodeoxycholic acid has been shown to improve bile flow and reduce hepatocyte injury in cholestatic liver disease. There is ongoing research into antifibrotic therapies, such as colchicine and pirfenidone, but these are not yet standard of care in veterinary medicine. Overall, the evidence supports a multimodal approach to management, with emphasis on treating the underlying cause, managing complications, and providing nutritional support.